Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of June 2018. The report primarily addresses corporate governance changes, specifically the resignation of a director and the subsequent review of the Board of Directors' composition to support the Company's clinical and business growth plans.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial statements or performance metrics.
Material Changes
- Director Resignation: Mr. Dov Hershberg resigned as a director effective June 3, 2018. He stated the resignation was due to personal reasons only and not due to any disagreement with the Company.
- Board Review: Following the appointment of Paul Sekhri as Chairman, the Board initiated a review of its composition to identify new members with managerial, business, and financial experience in the global pharma and biotech industry.
Outlook, Commentary, and Risks
Management indicated that the Company plans to enter the clinic in 2018 with its candidate COM701 and intends to pursue business opportunities from its pipeline and computational discovery capabilities. The Board anticipates that new prospective members will enhance growth and networking opportunities. The Company expects to disclose further information regarding the new Board composition within the coming weeks. No specific risks or contingencies were detailed in this filing.
Key Facts for Investor Verification
- Confirmation of the effective date of Mr. Hershberg's resignation (June 3, 2018).
- Timeline for the appointment of new Board members to replace the resigned director.
- Progress updates on the clinical entry of COM701 scheduled for 2018.
- Verification that the resignation was not related to any undisclosed disagreements or financial issues.